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Disparities in the Effects of Acuity Circle–based
Liver Allocation on Waitlist and Transplant Practice
Between Centers
Shunji Nagai, MD, PhD,1 Tommy Ivanics, MD, MPH,1 Toshihiro Kitajima, MD,1 Shingo Shimada, MD, PhD,1
Tayseer M. Shamaa, MD,1 Kelly Collins, MD,1 Michael Rizzari, MD,1 Atsushi Yoshida, MD,1 Dilip Moonka, MD,2
and Marwan Abouljoud, MD1

Background. Liver allocation in the United States was updated on February 4, 2020, by introducing the acuity circle
(AC)–based model. This study evaluated the early effects of the AC-based allocation on waitlist outcomes. Methods. Adult
liver transplant (LT) candidates listed between January 1, 2019, and September 30, 2021, were assessed. Two periods were
defined according to listing date (pre- and post-AC), and 90-d waitlist outcomes were compared. Median transplant Model
for End-stage Liver Disease (MELD) score of each transplant center was calculated, with centers categorized as low- (<25
percentile), mid- (25–75 percentile), and high-MELD (>75 percentile) centers. Results. A total of 12 421 and 17 078 LT candidates in the pre- and post-AC eras were identified. Overall, the post-AC era was associated with higher cause-specific 90-d
hazards of transplant (csHR, 1.32; 95% confidence interval [CI], 1.27-1.38; P < 0.001) and waitlist mortality (cause-specific
hazard ratio [csHR], 1.20; 95% CI, 1.09-1.32; P < 0.001). The latter effect was primarily driven by high-MELD centers. LowMELD centers had a higher proportion of donations after circulatory death (DCDs) used. Compared with low-MELD centers,
mid-MELD and high-MELD centers had significantly lower cause-specific hazards of DCD-LT in both eras (mid-MELD: csHR,
0.47; 95% CI, 0.38-0.59 in pre-AC and csHR, 0.56; 95% CI, 0.46-0.67 in post-AC and high-MELD: csHR, 0.11; 95% CI,
0.07-0.17 in pre-AC and csHR, 0.14; 95% CI, 0.10-0.20 in post-AC; all P < 0.001). Using a structural Bayesian time-series
model, the AC policy was associated with an increase in the actual monthly DCD-LTs in low-, mid-, and high-MELD centers
(actual/predicted: low-MELD: 19/16; mid-MELD: 21/14; high-MELD: 4/3), whereas the increase in monthly donation after
brain death–LTs were only present in mid- and high-MELD centers. Conclusions. Although AC-based allocation may
improve waitlist outcomes, regional variation exists in the drivers of such outcomes between centers.
(Transplantation Direct 2022;8: e1356; doi: 10.1097/TXD.0000000000001356).

T

he Final Rule states that organ allocation shall not be
based on the candidate’s residence or place of listing.1 The regional disparity of liver transplant (LT) access
has been an issue and has been extensively discussed. In

July 2018, a lawsuit was filed against Health Resources
and Services Administration regarding the disparity or LT
access between areas and called for the Organ Procurement
and Transplantation Network/United Network for Organ
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Sharing (OPTN/UNOS) to implement a new liver allocation policy not based on arbitrary Donation Service Areas
or Region Areas but rather as a zone-based liver distribution
policy.2 In response, OPTN/UNOS introduced the new liver
allocation policy, called acuity circle (AC)–based model, in
February 2020.3 The new model is based on radially oriented
zones around potential donors and involves converting each
transplant center’s median Model for End-stage Liver Disease
(MELD) score at transplant to reflect transplants performed
within a 250 nautical mile radius.
The OPTN/UNOS and LT society have been trying to
address the concerns about regional variation in LT access.4
One of the recent modifications in the LT allocation was the
“Share 35 rule,” introduced in 2013,5 which was only applied
within individual UNOS regions, and the discrepancies in
transplant MELD score between regions remained.6 The
AC-based model was proposed to further alleviate the concerns about the disparity in transplant access. The donor service area–based allocation was discarded, and donated livers
were shared based on radially oriented zones from the donor
hospitals. This has the potential to dramatically change LT
practice, along with having a downstream impact on patient
outcomes. It is therefore imperative to assess the effects of the
AC-based allocation on LT waitlist and transplant practice.
Recently, Chyou et al7 reported the first 6-mo effects of
AC-based allocation, demonstrating that adult non–status 1
deceased donor LT decreased by 2.7%. However, this report
evaluated the data from March 2020 to August 2020, during which time the coronavirus disease 2019 (COVID-19)
pandemic was declared, which significantly impacted LT
practice. The effect of the policy outside of a period affected
by the impact of COVID-19 remains to be fully elucidated.
Consequently, it may be beneficial to evaluate the initial
impact of AC-based allocation on LT waitlist outcomes and
practice using data in a period when the effects of COVID-19
have subsided.8 Wey et al9 recently also studied the effects of
AC-based allocation using more current data, demonstrating
that MELD 29–32 candidates consistently had the largest differences in deceased donor LT and offer rates compared with
before the implementation of the AC. However, the study by
Wey et al9 did not evaluate possible regional variation in the
effects of AC-based allocation. One of the main purposes of
introducing AC-based allocation was to reduce the regional
discrepancy of LT access. Therefore, thorough evaluations of
this aspect are crucial.
In this study, we hypothesized that there would be regional
differences in the effects of the AC-based allocation on waitlist and transplant practice. We aimed to evaluate the early
impact of the AC-based allocation on LT waitlist outcomes
and transplant characteristics and determine possible regional
variations.

MATERIALS AND METHODS
Patient Selection
This study uses data from the OPTN/UNOS Standard
Transplant and Research file, containing information from all
patients registered for LT in the United States until September
30, 2021. For the analysis of waitlist outcomes, candidate age
<18 y at listing, hepatocellular carcinoma (HCC) exception
cases, patients who were listed between February 5, 2020, and
May 9, 2020 (COVID-19 onset period),8 or who were listed
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before 2019 were excluded. The study was approved for an
institutional review board waiver after institutional review
board review.
Because AC-based allocation was introduced on February 4,
2020, 2 time periods were defined according to the date of LT
listing: a pre-AC era from January 1, 2019, to February 3, 2020,
and a post-AC era from May 10, 2020, to September 30, 2021.
May 10, 2020, was selected as the cutoff because the COVID-19
effects have been deemed to have stabilized according to
UNOS after that (COVID stabilization era).8
The median MELD score of each center from January 1,
2019, to February 3, 2020, (inclusive) was defined according
to the median MELD calculated based on MELD scores of
patients who received an LT, were age 12 or over, were not
status 1A or status 1B, did not receive a living donor graft, did
not receive a donation after circulatory death (DCD) graft,
and donors from hospitals located >500 nautical miles from
the recipient transplant hospital. This calculation of median
score followed the way of MELD score at transplant calculation by OPTN/UNOS. Quantiles were defined as <25 percentile as a MELD score ≤23, 25 percentile to 75 percentile as
a MELD score between 23 and 29, and >75 percentile as a
MELD score ≥29. According to this, transplant centers were
defined as lower, mid, and higher MELD center groups.
Analysis of Waitlist Outcomes
Ninety-day waitlist outcomes were analyzed using a competing risk analysis with outcomes, including improvement
on the waitlist (removal code 12), transplantation (removal
codes 2–4, 18, 19, 21, and 22), or death (including removal
for being too sick) (removal codes 5, 8, and 13). To eliminate
the effects of 2 different allocation policies, patients listed in
the pre-AC era were censored on February 4, 2020, if none of the
abovementioned events had occurred. Because differences in
follow-up time can result in withdrawal bias, patients who
were registered in either era were censored on the last day of
the respective era (February 4, 2020, and October 1, 2021,
respectively).10 Patients who received living donor liver transplantation were included in the waitlist outcome analyses
because they were also on deceased donor LT waitlist but
were censored at the time of living donor liver transplantation receipt in the waitlist outcome analyses.11 Outcomes
were compared between pre- and post-AC eras. Ninety-day
waitlist outcomes were also compared between eras in each
MELD region group. For the 90-d competing risk of donation after brain death (DBD) and DCD transplant, receipt of
DCD and DBD transplant was considered a competing event,
respectively.
For comparisons of variables in patients who received a
transplant, the 2 groups included patients listed pre-AC and
transplanted pre-AC and patients listed post-AC and transplanted post-AC. Patients listed pre-AC but transplanted
post-AC were thus excluded from the pre-AC group in the
abovementioned bivariate analysis (Figure 1). Patients who
received living donor liver transplantation were not included
in the analyses of transplant characteristics.
Structural Bayesian Time-series Model
To estimate the causal effect of the AC policy on monthly
transplant listings, DBD and DCD transplants, a time series
analysis was performed. Specifically, this analysis used a structural Bayesian time-series model to estimate how monthly

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
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FIGURE 1. Strengthening the Reporting of Observational Studies diagram of cohorts included and excluded. AC, acuity circle; COVID-19,
coronavirus disease 2019.

transplant listings, DBD and DCD transplants at low-, mid-,
and high-MELD centers might have evolved after the AC policy
if the policy had not occurred. Similarly, a sensitivity analysis
was performed to evaluate monthly listings with a MELD score
of >35 at listing in the low-, mid-, and high-MELD centers. A
fully Bayesian time-series estimate of the effect is computed; it
uses model averaging to construct the most appropriate synthetic control for modeling the counterfactual.12 In this time
series analysis, the pre- and post-AC periods were defined as
previously noted. Covariates selected for the modeling were
chosen based on the assumption that they would not be affected
by the AC policy and included albumin level at LT, LT candidate factors (height, weight, body mass index, primary payment
source at LT), and donor factors (height). Quantitative summaries are provided as tables displaying actual activity (what were
the transplant rates with the policy), predicted activity (what
would the transplant rates have been without the policy), absolute effect (with 95% confidence interval [CI]), relative effect
(with 95% CI), the posterior tail-area probability P, and the
posterior probability of a causal effect. A detailed description
of the structural Bayesian time-series method used is shown in
Text S1 (SDC, http://links.lww.com/TXD/A439).

Statistical Analysis
Descriptive data for continuous variables were expressed
as means with SD if the distribution was normal and medians with interquartile range if the distribution was nonnormal. These were compared using the Student t test and
Mann-Whitney U test, respectively. Categorical variables
were expressed as numbers and percentages and were compared using chi-square and Fisher exact test. For the waitlist
analysis, a cause-specific competing risk approach was used
to account for the presence of competing risks of transplant
and waitlist dropout because of mortality/being too sick for
transplant.13 To evaluate the effect of the exposure (AC policy) on competing events, cause-specific hazard ratios (csHRs)
were reported after adjustment for confounders. Variables
that were considered confounders were used for multivariable
adjustment included age at listing, MELD score at listing, gender, diabetes, functional status at listing (Karnofsky score 3
categories 70%–100%, 40%–60%, 10%–30%), life support
at listing, dialysis week before listing, hepatic encephalopathy at listing, alcohol-related liver disease, hepatitis C virus,
exception point case, and HCC. Quantitative summaries are
provided as tables displaying actual activity (what were the
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TABLE 1.

Patient characteristics stratified by AC era
Waitlist patient characteristics
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Gender, male, n (%)
Age at listing, median (IQR), y
BMI at listing, median (IQR), kg/m2
MELD at listing, median (IQR)
Life support at listing, n (%)
N-missing
Liver-kidney listing, n (%)
Dialysis week before listing, n (%)
N-missing
Non-HCC exception patients, n (%)
Primary liver disease, n (%)
Alcohol-related liver disease
Nonalcoholic steatohepatitis
Hepatitis C virus–related liver disease
Functional status at listing
N-missing
70%–100%, n (%)
40%–60%, n (%)
10%–30%, n (%)
MELD center
N-missing
Low, n (%)
Mid, n (%)
High, n (%)
Transplant patient characteristics
Distance donor hospital to transplant center (nautical miles), median (IQR)
Share type, n (%)
Local
Regional
National
DCD, n (%)
N-missing
CIT, median (IQR), h
Donor age, median (IQR), y
Recipient age at transplant, median (IQR), y
Recipient BMI at transplant, median (IQR), kg/m2
MELD at transplant, median (IQR)
Life support at transplant, n (%)
N-missing
Liver-kidney, n (%)
Dialysis week before transplant, n (%)
N-missing
Primary liver disease, n (%)
Alcohol-related liver disease
Nonalcoholic steatohepatitis
Hepatitis C virus–related liver disease
Functional status at transplant
N-missing
70%–100%, n (%)
40%–60%, n (%)
10%–30%, n (%)
MELD center
N-missing
Low, n (%)
Mid, n (%)
High, n (%)

Pre-AC (N = 12 421)

Post-AC (N = 17 078)

P

4900 (39.4)
57 (48–64)
28.4 (24.6–32.9)
20 (14–27)
564 (4.5)
5
1332 (10.7)
1252 (10.1)
11
555 (4.5)

6653 (39.0)
56 (47–63)
28.1 (24.4–32.6)
21 (14–29)
742 (4.5)
542
1678 (9.8)
1989 (11.6)
3
503 (2.9)

0.39a
<0.001b
<0.001b
<0.001b
0.82a

4794 (38.6)
3027 (24.4)
1575 (12.7)

7172 (42.0)
3958 (23.2)
1657 (9.7)

238
2430 (19.9)
4574 (37.5)
5179 (42.5)

947
3738 (23.2)
5617 (34.8)
6776 (42.0)

16
3678 (29.6)
5396 (43.5)
3331 (26.9)
Pre-AC (N = 5468)c
74 (9–216)

48
4894 (28.7)
7538 (44.3)
4598 (27.0)
Post-AC (N = 7675)
148 (40–314)

3423 (62.6)
1754 (32.1)
291 (5.3)
423 (8.2)
282
5.5 (4.3–6.8)
40 (28–53)
56 (47–63)
28.6 (24.8–32.9)
27 (20–35)
678 (12.4)
0
490 (9.0)
1122 (20.6)
34

2712 (35.3)
2275 (29.6)
2688 (35.0)
627 (8.6)
357
5.7 (4.6–6.9)
39 (28–52)
55 (45–62)
28.3 (24.5–32.9)
28 (21–35)
803 (10.5)
14
728 (9.5)
1748 (22.9)
30

2331 (42.6)
1325 (24.2)
493 (9.0)

3802 (49.5)
1714 (22.3)
545 (7.1)

95
2015 (37.5)
2126 (39.6)
1232 (22.9)

159
3049 (40.6)
2702 (35.9)
1765 (23.5)

0
1969 (36.0)
2327 (42.6)
1172 (21.4)

12
2516 (32.8)
3467 (45.2)
1680 (21.9)

<0.001a
<0.001a
<0.001b
<0.001a
0.02a
<0.001a
<0.001a

0.22a

<0.001a
<0.001b

0.41b
<0.001a
0.71a
<0.001a
0.09a
<0.001a
<0.001b
0.31b
0.003b

<0.001b
0.01b
<0.001b
<0.001b

<0.001b

Kruskal-Wallis rank-sum test.
Pearson chi-square test.
Includes a comparison of only patients who received a LT—pre-AC includes only patients listed pre-AC and transplanted pre-AC.
AC, acuity circle; BMI, body mass index; CIT, cold ischemia time; DCD, donation after circulatory death; HCC, hepatocellular carcinoma; IQR, interquartile range; LT, liver transplantation; MELD, Model
for End-stage Liver Disease.

a

b
c
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transplant rates with the policy), predicted activity (what
would the transplant rates have been without the policy),
absolute effect (with 95% CI), relative effect (with 95% CI),
the posterior tail-area probability P (1-sided), and the posterior probability of a causal effect. The posterior distribution
of the response variable (monthly DBD or DCD transplants)
expected in the absence of the intervention (AC policy). The
actual response is then compared with this posterior distribution. The tail-area probability is the probability under the
calculated posterior that the response is at least as extreme
(away from the expected value) as the one observed. A 2-sided
P < 0.05 was considered statistically significant for all other
analyses. All statistical analyses were performed using R
(R version 4.1.1 [2021-08-10], R foundation for Statistical
Computing, Vienna, Austria, http://www.R-project.org/). The
structural Bayesian time-series analysis was performed using
the package “CausalImpact” version 1.2.7.12

RESULTS
Patient Characteristics
During the study period, 36 981 patients were listed for LT.
Recipient age <18 y at listing (n = 1768), those who were listed
between February 5, 2020, and May 9, 2020 (n = 3234), and
HCC exception cases (n = 2480) were excluded (Figure 1).
There were 12 421 and 17 078 patients who were listed and
met the inclusion criteria in the pre- and post-AC eras, and a
total of 5468 and 9313 patients were listed and received LT in
the pre- and post-AC eras. The distance from donor hospital to
transplant center was longer in the post-AC era (74–148 miles;
P < 0.001), and the proportion of national sharing of organs
(sharing >250 nautical miles radius) was statistically significantly higher (5.3%–35.0%; P < 0.001). The cold ischemia
time was significantly longer in the post-AC era (median 5.5 h
pre-AC to 5.7 h post-AC; P < 0.001). The proportion of LTs
done was significantly lower in the lower MELD center group
post-AC (36.0% to 32.8%; P < 0.001) (Table 1).
When comparing characteristics in each MELD score center
group, a longer distance from the donor hospital to the transplant center and a larger proportion of national sharing in
the post-AC era were observed in all center groups (Table 2).
Notably, the proportion of DCD LTs in the post-AC era was
numerically higher in the lower MELD center group, but this
did not reach statistical significance (10.9%–12.0%; P = 0.27).
Similarly, the proportion of DCD LTs was not statistically significantly different between eras in the mid (8.5%–8.6%; P =
0.91) and higher MELD center groups (2.5%–3.2%; P = 0.31).
Comparisons of Waitlist Outcomes Between Eras
Waitlist outcomes were compared between the eras. In the
entire cohort, the 90-d probability of waitlist mortality was
not statistically significantly different (P = 0.34), although
the 90-d transplant probability was statistically significantly
higher in the post-AC era (P < 0.001) (Figure S1, SDC, http://
links.lww.com/TXD/A439). After risk-adjustment using
transplant candidate characteristics, the cause-specific hazard
of 90-d waitlist mortality associated with the post-AC era was
statistically significantly higher compared with the pre-AC era
(reference: pre-AC adjusted csHR, 1.20; 95% CI, 1.09-1.32;
P < 0.001). This effect was primarily attributed to the highMELD center groups. Moreover, post-AC was associated with
a higher 90-d cause-specific hazard of transplant compared
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with the pre-AC era (reference: pre-AC [csHR], 1.32; 95% CI,
1.27-1.38; P < 0.001) (Table 3).
Next, 90-d waitlist outcomes were compared stratifying by
MELD score center grouping. The 90-d transplant probability was statistically significantly higher in all groups in the
post-AC era. The 90-d probability of waitlist mortality was
statistically significantly higher in the post-AC era in only the
high-MELD center group (Figure S2, SDC, http://links.lww.
com/TXD/A439). In the lower MELD center group, although
the adjusted cause-specific hazard of 90-d waitlist mortality
was not statistically significantly different between the eras
(90-d mortality: csHR, 1.05; 95% CI, 0.85-1.29; P = 0.64),
the post-AC era was associated with a higher cause-specific
hazard of 90-d transplant (csHR, 1.17; 95% CI, 1.09-1.25;
P < 0.001). Similarly, in the mid-MELD center group, the
post-AC was associated with a nonstatistically significantly
different cause-specific hazard of waitlist mortality (csHR,
1.15; 95% CI, 0.99-1.33; P = 0.06) and a statistically significantly higher cause-specific hazard of 90-d transplant (csHR,
1.45; 95% CI, 1.36-1.53; P < 0.001). In the higher MELD
center group, post-AC was associated with a statistically significantly higher cause-specific hazard of 90-d waitlist mortality compared with pre-AC (csHR, 1.35; 95% CI, 1.15-1.59;
P < 0.001). Lastly, and similar to the low- and mid-MELD
center groups, the post-AC era was associated with a higher
cause-specific hazard of 90-d transplant than the pre-AC era
(csHR, 1.37; 95% CI, 1.26-1.49; P < 0.001) (Table 3).
Comparisons of 90-d Probability and Cause-specific
Hazard of Transplantation Between Center Groups
According to Donor Type
Because the AC-based model was designed to enhance
broader sharing of liver grafts from DBD donors, DBD and
DCD LT probabilities were examined separately. The 90-d
DBD LT probability was statistically significantly higher postAC in the low-, mid-, and high-MELD center groups (lowMELD pre-AC 43.4% versus post-AC 45.4%; P < 0.001;
mid-MELD pre-AC 35.0% versus post-AC 41.5%; P < 0.001;
and high-MELD pre-AC 29.0% versus post-AC 35.7%; P
= 0.002, <0.001, and <0.001, respectively) (Figure S3, SDC,
http://links.lww.com/TXD/A439). When comparing this
between MELD center groups in each era, the 90-d DBD LT
probability was significantly higher in the lower MELD center
group than in the mid or higher center groups in the pre-AC
era (P < 0.001), and this remained highest in the lower MELD
region group in the post-AC era (P < 0.001). Nonetheless, the
difference between centers was reduced in terms of the 90-d
DBD transplant probability in the post-AC era (Figure 2A and
B). After risk-adjustment, the mid-MELD (csHR, 0.64; 95%
CI, 0.59-0.69; P < 0.001) and high-MELD (csHR, 0.41; 95%
CI, 0.38-0.45; P < 0.001) center groups had a significantly
lower probability of DBD LT in the pre-AC era compared
with the low-MELD group. In the post-AC era, these differences were attenuated. The cause-specific DBD LT hazard
remained significantly higher in the low-MELD, compared
with mid-MELD (reference low: csHR, 0.78; 95% CI, 0.740.83; P < 0.001) and the high-MELD center groups (csHR,
0.47; 95% CI, 0.44-0.51; P < 0.001) (Table 4).
When comparing the 90-d DCD LT probability between
eras in each MELD center group, the low-MELD center group
had a nonstatistically significantly higher DCD LT probability post-AC (pre-AC 7.3% versus post-AC 8.3%; P = 0.27),
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TABLE 2.

Transplant donor characteristics for MELD centers stratified by AC era
Low-MELD centers
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Distance donor hospital to transplant center, median (IQR), nautical miles
Share type, n (%)
Local
Regional
National
DCD, n (%)
N-missing
CIT, median (IQR), h
Donor age, median (IQR), y
Mid-MELD centers
Distance donor hospital to transplant center, median (IQR), nautical miles
Share type, n (%)
Local
Regional
National
DCD, n (%)
N-missing
CIT, median (IQR), h
Donor age, median (IQR), y
High-MELD centers
Distance donor hospital to transplant center, median (IQR), nautical miles
Share type, n (%)
Local
Regional
National
DCD, n (%)
N-missing
CIT, median (IQR), h
Donor age, median (IQR), y

Pre-AC (N = 1969)a

Post-AC (N = 2516)

P

87 (9–249)

155 (42–314)

<0.001b
<0.001c

1198 (60.8)
605 (30.7)
166 (8.4)
207 (10.9)
65
5.1 (4.2–6.4)
40 (29–53)
Pre-AC (N = 2327)a
72 (10–198)

874 (34.7)
757 (30.1)
885 (35.2)
290 (12.0)
90
5.6 (4.6–6.7)
41 (30–54)
Post-AC (N = 3467)
140 (37–307)

1496 (64.3)
743 (31.9)
88 (3.8)
189 (8.5)
116
5.6 (4.5–6.9)
40 (28–53)
Pre-AC (N = 1172)a
55 (8–204)

1277 (36.8)
1073 (30.9)
1117 (32.2)
284 (8.6)
179
5.7 (4.5–6.9)
40 (29–53)
Post-AC (N = 1680)
166 (49–322)

729 (62.2)
406 (34.6)
37 (3.2)
27 (2.5)
101
5.8 (4.4–7.2)
37 (27–50)

554 (33.0)
445 (26.5)
681 (40.5)
51 (3.2)
88
5.8 (4.7–7.0)
36 (26–48)

0.27c
<0.001b
0.14b
<0.001b
<0.001c

0.91c
0.95b
0.78b
<0.001b
<0.001c

0.31c
0.26b
0.006b

Includes a comparison of only patients who received a LT—pre-AC includes only patients listed pre-AC and transplanted pre-AC.
Kruskal-Wallis rank-sum test.
Pearson chi-square test.
AC, acuity circle; CIT, cold ischemia time; DCD, donation after circulatory death; IQR, interquartile range; LT, liver transplantation; MELD, Model for End-stage Liver Disease.

a

b
c

Mortality

1.15 (0.99-1.33)

0.06

Transplant

1.45 (1.36-1.53)

<0.001

1.35 (1.15-1.59)
1.37 (1.26-1.49)

<0.001
<0.001

statistically significantly higher in the mid-MELD centers
(pre-AC 3.9% versus post-AC 4.9%; P = 0.02), whereas it
was nonstatistically significantly numerically higher in highMELD centers (high-MELD pre-AC 0.8% versus post-AC
1.3%; P = 0.14) (Figure S4, SDC, http://links.lww.com/TXD/
A439). The 90-d DCD LT probability was significantly higher
in the lower MELD center group both in the pre- and postAC eras (pre-AC era low 7.3% versus mid 3.9% versus 0.8%;
P < 0.001). This difference remained in the post-AC era (postAC low 8.3% versus mid 4.9% versus high 1.3%; P < 0.001)
(Figure 2C and D). This was corroborated by a consistently
lower adjusted cause-specific hazard of DCD LT in the midand high-MELD groups relative to the low-MELD group in
both the pre- and post-AC era. Notably, both the mid- and
high-MELD groups had a lower cause-specific hazard of
DCD transplant in the post-AC era ([reference low-MELD]
pre-AC mid-MELD csHR, 0.47; 95% CI, 0.38-0.59 to postAC csHR, 0.56; 95% CI, 0.46-0.67 and pre-AC high-MELD
csHR, 0.11; 95% CI, 0.07-0.17 to post-AC csHR, 0.14; 95%
CI, 0.10-0.20; all P < 0.001) (Table 4).

Adjusted for age at listing, MELD score at listing, gender, diabetes, functional status at listing, life
support at listing, dialysis week before listing, hepatic encephalopathy at listing, alcohol-related
liver disease, hepatitis C virus, exception point case, and hepatocellular carcinoma.
AC, acuity circle; CI, confidence interval; HR, hazard ratio; MELD, Model for End-stage Liver
Disease.

Bayesian Structural Time Series Analysis
The monthly transplant listings were examined using
Bayesian structural time series analysis. There was a

TABLE 3.

Impact of era (post-AC vs pre-AC) on 90-d waitlist outcomes
(cause-specific hazard)
Reference: pre-AC
Outcome
Overall
Mortality

Cause-specific HR (95% CI)

P

a

Transplant

1.20 (1.09-1.32)

<0.001

1.32 (1.27-1.38)

<0.001

Low-MELD center groupa
Mortality

1.05 (0.85-1.29)

0.64

Transplant

1.17 (1.09-1.25)

<0.001

Mid-MELD center groupa

High-MELD center groupa
Mortality
Transplant
a

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
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FIGURE 2. Comparisons of the 90-d cumulative incidence of DBD donor transplant and DCD donor transplant between MELD center groups:

(A) DBD LT pre-AC era, (B) DBD LT post-AC era, (C) DCD LT pre-AC era, and (D) DCD LT post-AC era. AC, acuity circle; CI, confidence interval;
DBD, donation after brain death; DCD, donation after circulatory death; LT, liver transplantation; MELD, Model for End-stage Liver Disease.

statistically significant increase in the monthly listings in the
low-, mid-, and high-MELD centers. On a sensitivity analysis,
this effect remained even for patients with an initial MELD
>35 at the time of listing in the low-, mid-, and high-MELD
centers.
We then evaluated the effect of the policy on monthly DCD
and DBD transplants within each center group. For the lowMELD centers, the policy had a positive effect on the monthly
DCD numbers (actual 19, predicted [SD] 16 [2]), corresponding to a relative increase of +20% (95% CI, –2% to –42%)
(Figure 3A). The probability of obtaining this effect by chance
was deemed to be very small (Bayesian 1-sided tail-area probability P = 0.04, meaning that the causal effect could be considered statistically significant). Similarly, the causal effect of
the AC policy on the monthly DCD transplants in mid- and
high-MELD centers was examined, and the relative effect
of the increase was higher than seen for the monthly DCD
in low-MELD centers (relative increase low-MELD centers
+20% [95% CI, –2% to –42%]; mid-MELD +46% [95%
CI, 21%-72%]; high-MELD +57% [95% CI, 31%-84%])
(Figure 3C and E). In contrast, there was no causal effect of
the policy on the monthly DBD transplants the low-MELD

centers but was associated with a relative increase in monthly
DBD transplants in both mid- and high-MELD centers (relative effect low-MELD –3% [not statistically significant];
mid-MELD +26% [95% CI, 15%-36%]; high-MELD +51%
[95% CI, 34%-70%]) (Figure 3B, D, and F).

DISCUSSION
This study examined the early effects of AC-based liver
allocation on waitlist outcomes and transplant practice. We
observed that the AC policy was associated with both an
increased 90-d transplant probability and waitlist mortality
overall. The effect on waitlist mortality was primarily driven
by high-MELD centers. Although the low-MELD centers had
the highest 90-d probability of transplantation in both the
pre- and post-AC era, the disparity between these rates was
reduced in the post-AC era. The difference in the 90-d probability of DCD transplant remained in the post-AC era, with
the low-MELD regions having a higher probability of DCD
transplantation relative to the mid- and high-centers in both
the pre-and post-AC era. This was further corroborated by the
time-series analysis, evaluating the causal impact of the policy
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TABLE 4.

Impact of MELD region (low [reference] vs mid vs high) on
90-d DBD and DCD cause-specific hazard
Reference: low-MELD center group
Outcome
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DBD
Pre-AC eraa
   Mid-MELD center group
   High-MELD center group
Post-AC eraa
   Mid-MELD center group
   High-MELD center group
DCD
Pre-AC eraa
   Mid-MELD center group
   High-MELD center group
Post-AC eraa
   Mid-MELD center group
   High-MELD center group

Cause-specific HR (95% CI)

P

0.64 (0.59-0.69)
0.41 (0.38-0.45)

<0.001
<0.001

0.78 (0.74-0.83)
0.47 (0.44-0.51)

<0.001
<0.001

0.47 (0.38-0.59)
0.11 (0.07-0.17)

<0.001
<0.001

0.56 (0.46-0.67)
0.14 (0.10-0.20)

<0.001
<0.001

Adjusted for age at listing, MELD score at listing, gender, diabetes, functional status at listing, life
support at listing, dialysis week before listing, hepatic encephalopathy at listing, alcohol-related
liver disease, hepatitis C virus, exception point case, and hepatocellular carcinoma.
AC, acuity circle; CI, confidence interval; DBD, donation after brain death; DCD, donation after
circulatory death; HR, hazard ratio; MELD, Model for End-stage Liver Disease.

a

on monthly DCD transplants, which demonstrated the policy
to have a positive effect on monthly DCD transplants in low-,
mid-, and high-MELD centers. Although the AC policy was
associated with a statistically significant increase in the DBD
monthly LTs in mid- and high-MELD centers, it did not have
a similar effect in low-MELD centers. The number of monthly
listings increased in low-, mid-, and high-MELD centers.
Although transplant access improved, this might not suffice
the increased needs of donated livers for very sick patients,
which could result in the increased risk of waitlist mortality.
Consequently, the AC-based allocation decreased the discrepancies in LT access between the centers, mainly for DBD LT.
This study revealed that the new allocation has been functioning as expected and seemed to appropriately alleviate the
concerns with the disparity of LT access.
It should be acknowledged that the early effects of
AC-based allocation were previously evaluated using the first
6-mo national LT data,7 which demonstrated that the volume of adult non–status 1 deceased donor LT decreased by
2.7%. The study period of their study overlapped the declaration of the COVID-19 pandemic. Although LT practice must
have been significantly affected by the COVID-19 pandemic
nationwide, the impact would have differed among regions
and states, especially at the beginning of the pandemic. To
reduce these effects, we considered the post-AC era after May
10, 2020, as the impact of the COVID-19 pandemic on transplant activity has been deemed to have stabilized by UNOS
(COVID 19 stabilization era).8 Although this study cohort
would not entirely eliminate the effects of the COVID-19 pandemic, the findings should support the significant effects of the
AC-based allocation observed in this study.
Before the introduction of the AC-based allocation, there
were concerns that broad sharing of donated livers might jeopardize waitlist outcomes in certain areas where MELD scores
at transplant were relatively low because it was expected that
a number of the donated livers in these areas would be shipped
out to other areas, leading to a lower chance of LT in these

areas.14 According to the findings of this study, the post-AC era
was associated with both an increased cause-specific waitlist
mortality and transplant hazard overall, the former primarily
driven by its effect in the high-MELD center group but not in
the low- or mid-MELD center group. Therefore, the concern
of possible adverse impact of AC-based allocation only in the
low-MELD centers was alleviated. However, the increase in
waitlist mortality in the high-MELD center group was unexpected and further investigations would be warranted.
The low-MELD centers had the highest probability of
DCD transplants compared with the mid- and high-MELD
centers in both the pre- and post-AC eras. Although the AC
policy had an effect of increasing DCD monthly transplants
in low-, mid-, and high-MELD centers, it had a statistically
significantly positive effect on monthly DBD transplants only
in mid- and high-MELD-center groups. Moreover, the relative positive effect of DCD monthly transplants was highest in
high-MELD centers. In the new allocation policy, DCD donors
and elderly donors (70 y or older) are allocated based on the
different logistics from those for DBD donors or younger
donors (<70 y).5 Although DBD donors are broadly allocated
based on AC, local allocation remains for DCD donors and
the disparities in DCD donor use between centers remained
significant. Low-MELD centers having the highest probability of DCD transplantation in both the pre- and post-AC era
may be reflection of the threshold for acceptability of such
grafts. Consequently, transplant centers which had many candidates with a low-MELD score might have more transplant
offers of DCD donors. They may therefore need to accept
more livers from DCD donors to maintain their LT activities.
Posttransplant outcomes in DCD LT had become comparable
with brain death donor LT.15,16 However, those excellent postLT outcomes were reported from well-experienced centers,
and it remains unclear if satisfactory outcomes in DCD LT
can be universally achieved. This study was unable to assess
post-LT outcomes because of the limited posttransplant follow-up period. It is crucial to evaluate the possible adverse
impact on outcomes secondary to the increase in the utilization of DCD donors and/or other types of marginal donors in
certain areas/transplant centers.17
Because the AC-based model might have a greater impact
on DBD donor liver allocation,3 this study evaluated the DBD
LT access in each group and assessed the regional discrepancies before and after introducing the AC-based allocation.
Notably, the disparity in the probability of 90-d DBD LT
decreased between regions in the post-AC era, largely driven
by increases in the mid- and high-MELD centers rather than
a decrease in low-MELD centers (low: 43.4%–45.4%, mid:
35.0%–41.5%, and high: 29.0%–35.7%). This reduced
disparity suggests that the purposes of the introduction of
the AC-based allocation have been successfully achieved.
Notably, although the AC-based model improved LT access,
we did not observe improvement in waitlist mortality. The
AC-based model changed geographic allocation, whereas the
medical urgency (patients’ ranking on the waitlist) remained
to be determined by the MELD-sodium (MELD-Na) score.
Recently, MELD 3.0 was proposed by Kim et al.18 According
to their report, MELD 3.0 could better identify waitlist mortality than MELD-Na, and they concluded that MELD 3.0
addresses the gender disparity in LT access. It should be noted
that the improvement in the MELD 3.0 model was subtle.
Our group recently created a waitlist mortality prediction

© 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

model using a neural network, a machine learning technique,
which had a significantly better performance of waitlist mortality prediction than the MELD-Na and the MELD 3.0 based
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model.19 To achieve further improvements in LT waitlist outcomes, improvements in the determination LT candidates’
medical urgency would be crucial as well.
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FIGURE 3. Time series analysis of monthly transplant trends pre- and post-AC policy. Each figure is comprised of 3 panels. 1. Original time

series (monthly transplant rates) and the counterfactual estimate (the light blue shaded area [what the monthly transplant rate would have been
had the policy not occurred]). 2. Difference between the observed data and the counterfactual estimate (point-wise causal effect). 3. Cumulative
causal effects over time. A, DCD in low-MELD centers, (B) DBD in low-MELD centers, (C) DCD in mid-MELD centers, (D) DBD in mid-MELD
centers, (E) DCD in high-MELD centers, and (F) DBD in high-MELD centers. AC, acuity circle; DBD, donation after brain death; DCD, donation
after circulatory death; MELD, Model for End-stage Liver Disease.
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Overall, the AC-based model provided positive changes in
the liver allocation. It should be noted that those improvements in waitlist outcomes occurred along with dramatic
changes in LT practice of transplant centers, which include
the substantial increase in the travel distance. Consequently,
cold ischemia time became significantly longer in all MELD
score center groups in the post-AC era. Broad organ sharing by the AC-based model allocation might enhance the
utilization of the donated livers for sicker patients with a
high-MELD score. Also, the characteristics of LT recipients
have been changing recently, which is represented by older
age and significant medical comorbidities such as obesity, diabetes, and cardiovascular diseases.20 These patient
populations may have less tolerance in using donor livers
with prolonged cold ischemia time.21,22 Therefore, possible
adverse effects of longer cold ischemia time should be evaluated in follow-up studies. Additionally, possible financial
burden secondary to longer travel distances, and potentially
higher cost for posttransplant care for sicker patients and
DCD graft pursuit, needs to be carefully assessed. Recently,
Wall et al23 reported an increase in cost associated with
liver acquisition that may be a threat to financial viability of transplant centers. Possible financial effects of the
AC-based allocation may be significant, for which further
studies would be warranted.
The limitations of this study should be acknowledged. The
OPTN/UNOS registry may contain the potential for misclassification. It is not possible to attribute a causal effect of the
AC-based allocation on outcomes in LT candidates, given the
nonrandomized, retrospective design with the potential for
unmeasured and residual confounding even despite the multivariable analyses performed. The post-AC era was chosen as
post–May 10, 2020, according to the UNOS’s deemed stabilization of the COVID-19 effect on transplant activity.8 Within
this context, there may be residual effects of the COVID-19
pandemic and may represent the potential of being a residual
confounder for these results. However, it should be acknowledged that the impact of COVID-19 pandemic on the LT practice was not uniform across the nation, and this might persist
and affect the practice differently during the study period of
our study. Therefore, future studies are necessary to examine
the effects of AC-based allocation after the end of the pandemic. Notwithstanding the COVID-19 pandemic having an
adverse impact on LT activities,24 a significant improvement in
LT access was observed in the post-AC era.
In conclusion, although the AC-based liver allocation
improved waitlist outcomes related to receipt of transplant,
regional variation of positive effects was observed. Although
there were significant differences in LT access between center
groups, these were successfully reduced by the introduction
of the AC-based allocation. Although the disparity between
centers with DBD transplants has decreased, the disparity
of DCD transplants between centers remained, with the AC
policy having a positive effect on the monthly DCD transplants in low-, mid-, and high-MELD centers, but with positive effects in monthly DBD transplants limited to mid- and
high-MELD centers. Notably, the changes in LT practice may
be the result of the allocation change, represented by the significant increase in travel distance and the regional variation
of DCD utilization, and the possible impact of these practice
changes on post-LT outcomes has not yet been determined.

Continuous evaluations are necessary to evaluate how those
changes affect the center- and region-level waitlist and postLT outcomes.
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